Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

277
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
277
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

334
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
334
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

245
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
245
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

310
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
310

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discontinuing Anti-VEGF Therapy in Patients with Neovascular Age-Related Macular Degeneration That Remains Inactive with Treatment at the Maximum Injection Interval.

Clinical ophthalmology (Auckland, N.Z.)·2026
Same author

Assessing Polypoidal Choroidal Vasculopathy-Related OCT Features in the TENAYA and LUCERNE Trials.

Ophthalmology science·2026
Same author

Advances in Polypoidal Choroidal Vasculopathy (PCV) Management: Emerging Evidence for Faricimab and Aflibercept 8 mg.

Ophthalmology and therapy·2026
Same author

Aflibercept With vs Without Reduced-Fluence Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: Optical Coherence Tomography Angiographic changes from a randomized clinical trial.

American journal of ophthalmology·2026
Same author

Fluorescein Angiography Leakage Patterns in Pachychoroid Neovasculopathy: Neovascularization or Central Serous Chorioretinopathy?

Ophthalmology and therapy·2026
Same author

Clinical outcomes of weekly adalimumab in refractory non-infectious paediatric uveitis and the role of serum drug levels and anti-adalimumab antibodies.

Eye (London, England)·2026
Same journal

Benchmarking and fine-tuning vision-language models on a visual question answering dataset for myopic maculopathy.

Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)·2026
Same journal

Does lens opacity matter? The effect of cataract on deep learning based cardiovascular disease risk scores from fundus photos.

Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)·2026
Same journal

Corrigendum to "Oculomics and AI: The eye as a biomarker for health span" [Asia-Pac J Ophthalmol 15 (1) (2026) 100282].

Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)·2026
Same journal

Visual preservation and surgical outcomes of phacogoniotomy in end-stage glaucoma: A multicenter study.

Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)·2026
Same journal

Association of asymmetrical normal tension glaucoma, obstructive sleep apnoea and side sleeping.

Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)·2026
Same journal

Mechanism of myopic axial elongation related to Bruch´s membrane.

Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)·2026
See all related articles

Related Experiment Video

Updated: Feb 11, 2026

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

3.2K

Pediatric Uveitis.

Nicole Shu-Wen Chan1, Jessy Choi2, Chui Ming Gemmy Cheung1,3,4

  • 1Singapore National Eye Centre, Singapore.

Asia-Pacific Journal of Ophthalmology (Philadelphia, Pa.)
|April 24, 2018
PubMed
Summary
This summary is machine-generated.

Pediatric uveitis presents unique challenges in children, often being chronic and resistant to treatment. Early diagnosis and multidisciplinary management are crucial for preventing vision loss and achieving long-term remission.

Keywords:
pediatric uveitis

More Related Videos

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

6.1K
Guidelines for Elective Pediatric Fiberoptic Intubation
11:19

Guidelines for Elective Pediatric Fiberoptic Intubation

Published on: January 17, 2011

18.6K

Related Experiment Videos

Last Updated: Feb 11, 2026

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

3.2K
Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

6.1K
Guidelines for Elective Pediatric Fiberoptic Intubation
11:19

Guidelines for Elective Pediatric Fiberoptic Intubation

Published on: January 17, 2011

18.6K

Area of Science:

  • Ophthalmology
  • Pediatric Medicine
  • Inflammatory Diseases

Background:

  • Pediatric uveitis is distinct from adult-onset forms, posing significant diagnostic and therapeutic challenges.
  • Children often present asymptomatically with chronic, persistent, and treatment-resistant uveitis.
  • Anterior uveitis is most common, with variable prevalence of other types geographically and ethnically.

Purpose of the Study:

  • To highlight the unique characteristics of pediatric uveitis.
  • To discuss the diagnostic and therapeutic challenges.
  • To emphasize the importance of timely and comprehensive management for preventing visual disability.

Main Methods:

  • Review of existing literature on pediatric uveitis.
  • Analysis of common etiologies, including idiopathic, systemic inflammatory disorders, infections, and masquerade syndromes.
  • Examination of ocular complications and treatment strategies.

Main Results:

  • Common complications include cataracts, glaucoma, macular edema, and retinal detachment, often leading to irreversible damage.
  • Treatment involves a stepwise approach, starting with corticosteroids and progressing to immunomodulatory therapy if needed.
  • Steroid dependence and delayed initiation of disease-modifying agents contribute to poor outcomes.

Conclusions:

  • Achieving steroid-free remission and preventing sight-threatening complications are key goals.
  • Multidisciplinary management ensures holistic care and improves support for affected children and families.
  • Regular monitoring for uveitis complications and treatment side effects is essential.